{"id":"ventavis-iloprost-bayq6256","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Headache"},{"rate":"20-30%","effect":"Nausea"},{"rate":"10-20%","effect":"Dizziness"},{"rate":"10-20%","effect":"Flushing"},{"rate":"5-10%","effect":"Pain in extremity"},{"rate":"5-10%","effect":"Palpitations"},{"rate":"5-10%","effect":"Cough"},{"rate":"5-10%","effect":"Dyspnea"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL5315118","moleculeType":"Small molecule","molecularWeight":"481.63"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Iloprost works by binding to and activating prostacyclin receptors, leading to relaxation of vascular smooth muscle and vasodilation. This results in decreased pulmonary artery pressure and resistance, improving exercise capacity and symptoms in patients with pulmonary arterial hypertension.","oneSentence":"Ventavis is a prostacyclin analogue that acts as a vasodilator to improve exercise capacity in patients with pulmonary arterial hypertension.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:40:27.024Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of pulmonary arterial hypertension"}]},"trialDetails":[{"nctId":"NCT07450469","phase":"","title":"Field Study on Intravenous Iloprost for Treatment of Severe Frostbite at High Altitude","status":"NOT_YET_RECRUITING","sponsor":"Institute of Mountain Emergency Medicine","startDate":"2026-05","conditions":"Frostbite, Altitude, Field Physician Care","enrollment":10},{"nctId":"NCT02825160","phase":"","title":"Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-08-01","conditions":"Hypertension, Pulmonary","enrollment":282},{"nctId":"NCT03293407","phase":"","title":"Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-02-01","conditions":"Hypertension, Pulmonary","enrollment":31},{"nctId":"NCT01389271","phase":"","title":"Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-02-03","conditions":"Pulmonary Hypertension","enrollment":118},{"nctId":"NCT01971450","phase":"","title":"Non-interventional Study on Compliance of Inhaled Treatment With Ventavis in Patient With Pulmonary Hypertension","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-11-21","conditions":"Hypertension, Pulmonary","enrollment":89},{"nctId":"NCT02032836","phase":"PHASE1, PHASE2","title":"Comparative PK PD Study in PAH Patients (Fox vs. I-Neb)","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-03-10","conditions":"Pulmonary Arterial Hypertension","enrollment":27},{"nctId":"NCT01894035","phase":"","title":"Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-09-23","conditions":"Pulmonary Hypertension","enrollment":13},{"nctId":"NCT01469169","phase":"PHASE3","title":"Inhaled Iloprost (Ventavis): Efficacy, Safety, and Pharmacokinetics (PK) Confirmation Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-06-19","conditions":"Hypertension, Pulmonary","enrollment":27},{"nctId":"NCT01781052","phase":"","title":"Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-09-11","conditions":"Pulmonary Arterial Hypertension","enrollment":17},{"nctId":"NCT01355380","phase":"","title":"Efficacy of Ventavis Used in Real-life Setting.","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-08-05","conditions":"Pulmonary Arterial Hypertension","enrollment":55},{"nctId":"NCT02826252","phase":"","title":"Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-09-15","conditions":"Hypertension, Pulmonary","enrollment":64},{"nctId":"NCT01458041","phase":"","title":"Iloprost Therapy in Patients With Critical Limb Ischemia","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-08","conditions":"Peripheral Arterial Disease","enrollment":126},{"nctId":"NCT00250640","phase":"","title":"Observation of Patients With Primary Pulmonary Hypertension Receiving Prescribed Ventavis Inhalation Therapy Regarding Safety and Efficacy for up to 4 Years","status":"COMPLETED","sponsor":"Bayer","startDate":"2005-04","conditions":"Hypertension, Pulmonary","enrollment":106},{"nctId":"NCT01468545","phase":"","title":"Educational Training Influence in Patients With PAH(Pulmonary Artery Hypertension) on Inhaled Ventavis Treatment Adherence Evaluated Trough INSIGHT System","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-10","conditions":"Pulmonary Arterial Hypertension","enrollment":38},{"nctId":"NCT01062282","phase":"","title":"Hypertension Study of Ventavis® Inhalation Therapy in the Treatment of Patients With Pulmonary Arterial Hypertension (VENIS)","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-07","conditions":"Pulmonary Hypertension","enrollment":41},{"nctId":"NCT00185315","phase":"PHASE3","title":"Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension","status":"COMPLETED","sponsor":"Bayer","startDate":"2000-02","conditions":"Hypertension, Pulmonary","enrollment":71},{"nctId":"NCT00414687","phase":"PHASE2","title":"Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension","status":"COMPLETED","sponsor":"Bayer","startDate":"1998-07","conditions":"Hypertension, Pulmonary","enrollment":63},{"nctId":"NCT00882947","phase":"","title":"Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-02","conditions":"Primary Hypertension","enrollment":38}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ventavis (Iloprost, BAYQ6256)","genericName":"Ventavis (Iloprost, BAYQ6256)","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ventavis is a prostacyclin analogue that acts as a vasodilator to improve exercise capacity in patients with pulmonary arterial hypertension. Used for Treatment of pulmonary arterial hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}